Research and Development Expenses Breakdown: Teva Pharmaceutical Industries Limited vs BioMarin Pharmaceutical Inc.

R&D Spending: A Tale of Two Strategies

__timestampBioMarin Pharmaceutical Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20144615430001488000000
Thursday, January 1, 20156348060001525000000
Friday, January 1, 20166619050002111000000
Sunday, January 1, 20176107530001848000000
Monday, January 1, 20186963280001213000000
Tuesday, January 1, 20197150070001010000000
Wednesday, January 1, 2020628116000997000000
Friday, January 1, 2021628793000967000000
Saturday, January 1, 2022649606000838000000
Sunday, January 1, 2023746773000953000000
Monday, January 1, 2024747184000998000000
Loading chart...

Unleashing the power of data

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, BioMarin Pharmaceutical Inc. and Teva Pharmaceutical Industries Limited have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, BioMarin's R&D expenses grew by approximately 62%, peaking in 2023. This steady increase underscores BioMarin's commitment to pioneering treatments for rare diseases. In contrast, Teva's R&D spending saw a decline of about 36% over the same period, reflecting a strategic shift amidst industry challenges. Notably, Teva's highest R&D expenditure was in 2016, coinciding with its aggressive expansion phase. These trends highlight the dynamic nature of pharmaceutical innovation, where strategic investments in R&D can shape the future of healthcare. As the industry evolves, understanding these financial commitments offers valuable insights into the companies' long-term visions and market positioning.

R&D Spending: A Tale of Two Strategies

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025